AVITA Medical, Inc. (AVH.AX)
| Previous close | 2.4800 |
| Open | 2.4100 |
| Bid | 2.3800 x 734600 |
| Ask | 2.4700 x 258500 |
| Day's range | 2.3800 - 2.4700 |
| 52-week range | 2.3800 - 6.2700 |
| Volume | |
| Avg. volume | 335,570 |
| Market cap | 307.018M |
| Beta (5Y monthly) | 1.42 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.5300 |
| Earnings date | 08 Aug 2024 - 12 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 4.47 |
GlobeNewswireAVITA Medical to Host Investor Webinar Briefing
VALENCIA, Calif., May 16, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, invites shareholders and prospective investors to attend its investor webinar briefing and presentation by Jim Corbett, Chief Executive Officer, and David O’Toole, Chief Financial Officer, on May 21, 2024, at 4:00 p.m. Pacific Daylight Time / May 22, 2024, at 9:00 a.m. Au
- GuruFocus.com
AVITA Medical Inc (AVHHL) (Q1 2024) Earnings Call Transcript Highlights: Navigating Challenges ...
Despite a challenging quarter, AVITA Medical Inc (AVHHL) reaffirms full-year revenue guidance and progresses on strategic initiatives.
- GlobeNewswire
AVITA Medical Reports First Quarter Financial Results
VALENCIA, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today reported financial results for the first quarter ended March 31, 2024. Financial Results and Recent Business Updates Commercial revenue increased approximately 5.8% to $11.1 million compared to the same period in 2023Gross profit margin of 86.4%Launched PermeaDerm,
